Loading organizations...

§ Venture Capital · VA, USA
Private investment firm providing capital and expertise for tech and biotech startups in USA and Canada, leveraging 25+ years of experience.
Cobro Ventures is an active private investment firm based in McLean, Virginia, that provides venture capital and operational expertise to early-stage technology and biotechnology startups. The firm primarily targets seed and Series A funding rounds across the United States and Canada, focusing on emerging sectors such as artificial intelligence, health technology, and synthetic miniprotein therapeutics. Operating with a concentrated team of between five and seven employees, the investment firm reported approximately $4 million in total revenue during the 2024 fiscal year. The organization leverages the extensive operational experience of its leadership team, which includes Chief Scientific Officer Dennis Klinman, Uriah Adams, and the corporate legacy of enterprise software company OPNET Technologies. While its exact founding year remains undisclosed, Cobro Ventures was established by the late Marc A. Cohen alongside the original founding entrepreneurs behind OPNET Technologies.
Key people at Cobro Ventures.
Cobro Ventures was founded in 2012 by Alain Cohen (Co-founder and CEO).
Cobro Ventures was founded in 2012 by Alain Cohen (Co-founder and CEO).
Cobro Ventures is a US-based private investment firm specializing in biotechnology and technology sectors, particularly software. With a team that has over 25 years of experience as founders, operators, and investors, the firm focuses on supporting early-stage companies through critical phases of innovation by providing capital, expertise, and strategic resources. Their mission centers on "doing well by doing good," aiming to create significant value by backing world-class scientific and technology experts and leveraging intellectual property and business development[2][1][3].
Founded by entrepreneurs behind OPNET Technologies, Inc., Cobro Ventures has a track record of successful exits via IPOs and acquisitions, particularly in biotech and tech startups. Their portfolio includes companies advancing selective HDAC inhibition, targeted protein degradation, synthetic miniprotein therapeutics, AI-guided therapy, and private online community platforms. The firm’s investment philosophy emphasizes impactful innovation and strategic growth in sectors with high scientific and technological potential[2][5].
Cobro Ventures was launched by the founders of OPNET Technologies, leveraging their entrepreneurial and operational experience to transition into venture investing. The firm has evolved to focus primarily on biotech and software startups across the US, building on a 20+ to 25+ year track record of founding and scaling technology businesses. Key partners include Marc A. Cohen (late co-founder and CEO) and Todd Kaloudis (Managing Director and General Partner), who have shaped the firm’s mission and investment approach[2][5][3].
Cobro Ventures rides the wave of rapid innovation in biotechnology and software, sectors driven by advances in molecular biology, AI, and digital transformation. The timing is critical as biotech breakthroughs and software platforms increasingly intersect, creating new therapeutic and technological paradigms. The firm’s influence extends by nurturing startups that push scientific boundaries and digital innovation, thereby shaping the ecosystem of early-stage ventures that fuel long-term industry growth[2][1].
Looking ahead, Cobro Ventures is well-positioned to capitalize on emerging trends such as targeted protein degradation, AI-driven therapies, and digital community platforms. Their continued emphasis on combining deep scientific expertise with operational experience suggests they will remain influential in bridging innovation and commercialization. As biotech and tech sectors evolve, Cobro Ventures’ role as a strategic partner and investor will likely expand, fostering startups that address critical health and technology challenges while generating substantial economic value[2][1].
This outlook ties back to their founding ethos of "doing well by doing good," reflecting a commitment to impactful innovation and sustainable growth in the technology and biotech arenas.
Key people at Cobro Ventures.
Cobro Ventures has 8 tracked investments across 7 companies. The latest tracked deal is $41.5M Series A in AI Proteins in November 2025.